Celcuity Inc, based in Minneapolis, MN, is a clinical stage biotechnology company specializing in discovering previously undetectable cancer drivers and developing targeted therapies to treat them. Their third-generation cellular analysis platform provides unparalleled insights into oncogenic pathways, leading to the development of new potential applications for targeted therapies.
With a focus on unraveling complex oncogenic activity that traditional molecular tests cannot detect, Celcuity's lead candidate is gedatolisib, a dual PI3K mTOR inhibitor. Through comparative analyses using live patient tumor cells, the company aims to create first-in-class drugs and deliver hope to cancer patients by providing innovative treatment options.
Generated from the website